VEGFR/PDGFR dual kinase inhibitor TAK-593
Term · Oncology and biomedicine · MLC-T-ONC-017482
An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.
| Identifier | MLC-T-ONC-017482 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017482",
"term": "VEGFR/PDGFR dual kinase inhibitor TAK-593",
"field": "Oncology and biomedicine",
"definition": "An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vegfr-pdgfr-dual-kinase-inhibitor-tak-593/"
}
Record 17,171 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.